Anti-PD1 therapies induce an early expansion of Ki67+CD8+ T cells in metastatic non-oncogene addicted NSCLC patients

Pembrolizumab (an anti-PD1 antibody) alone or combined with chemotherapy represented the standard of care for advanced non-oncogene addicted non-small cell lung cancer (NSCLC) patients. These therapies induced early modifications of the immune response impacting the clinical outcome. Identifying ear...

وصف كامل

التفاصيل البيبلوغرافية

المؤلفون الرئيسيون:	Alain Gelibter, Lucrezia Tuosto, Angela Asquino, Marco Siringo, Arianna Sabatini, Ilaria Grazia Zizzari, Angelica Pace, Fabio Scirocchi, Flavio Valentino, Serena Bianchini, Salvatore Caponnetto, Donatella Paoli, Filippo Bellati, Daniele Santini, Marianna Nuti, Aurelia Rughetti, Chiara Napoletano
التنسيق:	Artigo
اللغة:	Inglês
منشور في:	Frontiers Media S.A. 2024-12-01
سلاسل:	Frontiers in Immunology
الموضوعات:	NSCLC immune checkpoint inhibitors anti-PD-1 lymphocytes CD137
الوصول للمادة أونلاين:	https://www.frontiersin.org/articles/10.3389/fimmu.2024.1483182/full
الوسوم:	إضافة وسم لا توجد وسوم, كن أول من يضع وسما على هذه التسجيلة!